AKT1 and osteosarcoma: RUNX3 overexpression rescued these effects, confirming it as a functional target.<h4>Conclusion</h4>miR-495 acts as a tumor suppressor in osteosarcoma by targeting RUNX3 to inhibit PI3K/Akt signaling, suggesting its potential as a prognostic marker and therapeutic target.